Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study
Objectives We assessed the safety, tolerability, pharmacokinetics, preliminary antitumour activity and pharmacodynamics of danvatirsen, an antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3), monotherapy and danvatirsen plus durvalumab, an antiprogrammed ce...
Main Authors: | Yasutoshi Kuboki, Tomohiro Nishina, Tomoko Fujita, Naoto Yoshizuka, Ko Sugibayashi, Kosho Murayama |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-10-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/10/e055718.full |
Similar Items
-
Silencing Antibiotic Resistance with Antisense Oligonucleotides
by: Saumya Jani, et al.
Published: (2021-04-01) -
In-silico study of antisense oligonucleotide antibiotics
by: Erica S. Chen, et al.
Published: (2023-11-01) -
Antisense Oligonucleotides: Concepts and Pharmaceutical Applications
by: Ariana Araya, et al.
Published: (2023-02-01) -
Selective targeting of MYC by antisense oligonucleotides
by: Gill, Taylor Elizabeth
Published: (2018) -
Wrangling RNA: Antisense oligonucleotides for neurological disorders
by: Talbot, K, et al.
Published: (2019)